Leading US hospital improves surgical outcomes

RNS Number : 5753P

Deltex Medical Group PLC

09 June 2015

 

9 June 2015

Deltex Medical Group plc

("Deltex Medical", "the Company" or "the Group")

Leading US hospital improves surgical outcomes with ODM

Deltex Medical, the global leader in oesophageal Doppler monitoring ("ODM"), announces results from implementation of ODM at a US platform programme account.

Doctors from one of the most prestigious hospitals in the USA, Brigham and Women's Hospital in Boston, Massachusetts, presented the results from introduction of ODM as a quality improvement initiative in colorectal surgery at the 2015 meeting of the American Society for Colon and Rectal Surgeons.

ODM was one of the main changes made to introduce an enhanced recovery approach to surgery. Results highlights included:

·    18.5% of patients discharged on day two after surgery (historic control: 1.7% of patients discharged on day two)

·    25% reduction in both median and mean length of stay

·    >80% reductions in both post-operative cardiac events and wound infections

·    earlier return to diet and bowel function

Based on these results, the hospital's leadership has recommended making the enhanced recovery protocols, including ODM, the default protocol for all colorectal surgeries, with the potential to expand into other surgical areas such as urology and gynaecology.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We are delighted that our dedicated trainer programme has helped deliver excellent results from such a high calibre and renowned US hospital as Brigham and Women's. This convergence of our US platform and market development programmes is important validation of our focused strategy to build our US business towards future national roll-out."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson	020 7533 7727
Financial Public Relations
Newgate	020 7653 9850
Tim Thompson
Robyn McConnachie Ed Treadwell

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

NRALLFSDRTITIIE